# Identification of different receptor types for toxic phospholipases A2 in rabbit skeletal muscle

# Gérard Lambeau, Jacques Barhanin and Michel Lazdunski

Institut de Pharmacologie Moléculaire et Cellulaire, 660 route des Lucioles, Sophia Antipolis 06560 Valbonne, France

Received 20 september 1991

Oxyuranus scutellatus toxins 1 (OS<sub>1</sub>) and 2 (OS<sub>2</sub>) are two phospholipase A<sub>2</sub>s (PLA<sub>2</sub>) isolated from the venom of the Australian Taipan snake. Their iodinated derivatives have been used to characterize PLA, binding sites on rabbit skeletal muscle. Competition and cross-linking experiments indicate that 1251-labelled OS2 binding sites in rabbit skeletal muscle in vivo are distributed into two classes of receptors. One class binds OS, and OS, and is insensitive to the bee venom PLA2. It is composed of a 180 kDa binding protein. This class of PLA2 receptor is expressed at a high level in rabbit myotube membranes. The other class of PLA2 receptor identified with 1251-OS, also binds with high affinity the bee venom PLA, but not OS, and is composed of major polypeptides of 34, 48 and 82 kDa. This second class of receptor is similar to the one found in brain membranes. The density of the two classes of receptors varies during muscle development.

Skeletal muscle; Neurotoxin; Myotoxin; Phospholipase A2: Snake venom

### I. INTRODUCTION

Snake venom phospholipase A<sub>2</sub> (PLA<sub>2</sub>s), EC 3.1.1.4, form a large family of enzymes exerting a variety of toxic effects in mammals [1], which may be neurotoxic [2], cardiotoxic [3], and/or myotoxic [4]. Many of them also have anticoagulant [5] and hemolytic [6] effects. The neurotoxicity of these presynaptically active neurotoxins does not seem to correlate with their phospholipase activity [7]. In fact, the different types of toxicity of the different venom PLA<sub>2</sub>s may be due to the presence of different specific binding sites which we have recently identified for these toxic enzymes in different tissues. Specific binding sites for neurotoxic PLA2s have been characterized on rat brain synaptosomes with a radio-iodinated derivative of a neurotoxic PLA2 isolated from the venom of the Australian taipan snake Oxyuranus scutellatus scutellatus called OS, [8]. These binding sites are of very high affinity for the toxin and are protein in nature. High affinity PLA, binding sites for OS, have also been identified in cultured rabbit muscle cells and purified to homogeneity from this biological source [9]. Affinity labeling and purification studies have shown that myotube and neuronal OS<sub>2</sub> binding sites are, surprisingly, composed of different protein subunits.

The work reported here extends our previous results on PLA, binding sites and definitely shows that there exist two types (at least) of PLA<sub>2</sub> receptors as it shows

Correspondence address: M. Lazdunski. Institut de Pharmacologie Moléculaire et Cellulaire, 660 route des Lucioles, Sophia Antipolis 06560 Valbonne, France. Fax: (33) (93) 957704.

several types of receptors for most hormones and neurotransmitters. Both neuronal and myotube types of OS, receptors can in fact be found in skeletal muscle. The respective proportion of thes two types of receptors varies with development.

#### 2. MATERIALS AND METHODS

OS<sub>1</sub> and OS<sub>2</sub> from Oxyuranus scutellatus scutellatus and PLA<sub>2</sub> from Apis mellifera venoms were purified as previously described [8,10]. Na 125I (IMS30) was from Amersham Corp. All other reagents were of analytical grade.

#### 2.2. Indination of OS, and OS,

The iodination procedure was described previously [8,9]. The specific radioactivity was routinely 3000-3500 cpm/fmol of toxin.

#### 2.3. Membrane preparations

Crude microsomal fractions of skeletal muscle and membrane fractions of myotubes were prepared as previously described [9,11]. Protein concentrations were determined according to Bradford [12] after digestion of membranes in 0.1 N NaOH and using bovine serum albumin as a standard.

### 2.4. Binding studies

All binding experiments were performed ad 20°C in a buffer consisting of 20 mM Tris-HCl, pH 7.4, 140 mM NaCl, 0.1 mM CaCl<sub>2</sub>, and 0.1% bovine serum albumin. Membranes were incubated with the radiolabeled ligand in the absence or presence of unlabeled competitor for 1 h before filtration [8]. Routinely, and except where otherwise specified, the incubation volumes were 0.5 and 1 ml for  $^{125}$ I-OS<sub>1</sub> and  $^{125}$ I-OS<sub>2</sub> binding, respectively.

# 2.5. Cross-linking experiments

Membranes (0.3 mg/ml) were incubated in 1 ml of a 20 mM HEPES buffer, pH 7.4, containing 140 mM NaCl. 0.1 mM CaCl. and 0.1% bovine serum albumin with 300 pM 1251-OS2 or 250 pM 1251-OS1 in the absence or the presence of varying concentrations of unlabeled toxin. After 45 min at 20°C, incubation mixtures were centrifuged at 12 000  $\times$  g for 10 min and resuspended in 1 ml of 20 mM HEPES, pH 8.2, 140 mM NaCl. 0.1 mM CaCl<sub>2</sub>. Following the addition of 50  $\mu$ M suberic acid bis-N-hydroxysuccinimide ester (DSS, Sigma,freshly dissolved in Me<sub>2</sub>SO at 5 mM) for 5 min at 20°C, the reaction was stopped by addition of 100  $\mu$ l of 1 M Tris-HCl, pH 8.0, and centrifugation at 12 000  $\times$  g for 10 min. Resulting pellets were solubilized with an SDS sample buffer [13] under reducing conditions (4% B-mercaptoethanol) and analyzed by SDS polyacrylamide gel electrophoresis [13]. Gels were stained with Coomassie brilliant blue, dried, and autoradiographed at -70°C using Kodak X Omat AR films and intensifying screen (Du Pont Cronex Hi-plus).

# 3. RESULTS AND DISCUSSION

OS<sub>2</sub> and OS<sub>1</sub> are two different toxic phospholipases from taipan venom [8]. It has been shown previously that <sup>125</sup>I-OS<sub>1</sub> shares the same binding sites as <sup>125</sup>I-OS<sub>2</sub> in rabbit myotube membranes but that it does not bind with high affinity to rat brain membranes [8,9].

Fig. 1 illustrates equilibrium binding experiments performed on a microsomal preparation from adult rabbit skeletal muscle using  $^{125}\text{I-OS}_2$  (Fig. 1A) and  $^{125}\text{I-OS}_1$  (Fig. 1B) as ligands. Maximal binding capacities  $(B_{\text{max}})$  were  $8 \pm 3$  (n = 3) and  $2 \pm 1.4$  (n = 4) fmol/mg of proteins for  $^{125}\text{I-OS}_2$  and  $^{125}\text{I-OS}_1$ , respectively. These low binding capacities were determined with an accepta-

ble accuracy because of the very high specific radioactivities of the two toxins (55 TBq/mmol) and of the low level of non-specific binding.

The binding properties of these PLA<sub>2</sub>s to adult skeletal muscle membranes were very different from those preciously described for membranes from skeletal muscle cells in culture, for which the  $B_{\text{max}}$  values for <sup>125</sup>1-OS<sub>2</sub> and <sup>125</sup>I-OS<sub>1</sub> were considerably higher (1800–2200 fmol/ mg of protein) and essentially identical for the two toxins [9]. Scatchard plots obtained for 125 I-OS2 binding to membranes of embryonic (18-day-old embryos) rabbit skeletal muscle are presented in Fig. 1C. In this case specific 125I-OS<sub>2</sub> binding was best fitted with a model involving the presence of 2 families of binding sites. The very high affinity component has a Kd of 2± 1.5 pM and a  $B_{\text{max}}$  of 67 ± 15 fmol/mg of protein (n = 3); the lower affinity component has a  $K_d$  of 33  $\pm$  9 pM and a  $B_{\text{max}}$  of 203 ± 35 fmol/mg of protein. When <sup>125</sup>I-OS<sub>1</sub> was used as ligand, only one family of binding sites was detected with a  $K_d$  of 48  $\pm$  10 pM and a  $B_{\text{max}}$  of 40  $\pm$ 12 fmol/mg of protein (n = 3) (Fig. 1D). Fig. 2 shows that specific 125I-OS<sub>1</sub> binding was totally inhibited by both unlabeled  $OS_1$  and  $OS_2$  with  $K_{0.5}$  values of 32 and 18 pM, respectively, whereas Fig. 3 shows that unlabeled OS, only partially (~20%) inhibited 125 I-OS, bind-




Fig. 1. Equilibrium binding of <sup>125</sup>I-OS<sub>2</sub> (panel A and C) or <sup>125</sup>I-OS<sub>1</sub> (panel B and D) to rabbit skeletal muscle microsomal membranes of adult (panel A and B) or 18-day-old embryos (panel C and D). Main panels: membranes (550, 740, 10 and 450 µg of protein/ml in A, B, C and D, respectively) were incubated with increasing concentrations of radiolabeled toxin in the absence (•, total binding) or the presence (C), non-specific binding) of 2 nM unlabeled OS<sub>2</sub> (A and C) or 30 nM unlabeled OS<sub>3</sub> (B and D). Insets: Scatchard plot of specific binding components for <sup>125</sup>I-OS<sub>2</sub> and <sup>125</sup>I-OS<sub>3</sub>, respectively. B, Bound <sup>125</sup>I-toxin in pmol/mg of protein; F, free <sup>125</sup>I-toxin in nM. The straight lines represented in inset C were derived from a fitting of the data based on the presence of two families of independent binding sites.

ing with a  $K_{0.5}$  value of 41 pM. This suggests that <sup>125</sup>I-OS<sub>1</sub> binding sites represent only a part of the total population of <sup>125</sup>I-OS<sub>2</sub> binding sites.

All binding parameters for <sup>125</sup>I-OS<sub>2</sub> and <sup>125</sup>I-OS<sub>1</sub> determined on membranes of skeletal muscle cells at the embryonic or at the adult stage and on membranes of cultured myotubes are listed in Table I. Results from experiments performed on muscle from young (4-dayold) rabbits have also been included. The first observation is that the overall density of 125I-OS2 binding sites decreases drastically from 1900 ± 200 in muscle cells in culture to 8 ± 3 fmol/mg of protein in adult muscle tissue. The OS, binding site density also decreases dramatically from  $1820 \pm 150$  to  $2 \pm 1.4$  fmol/mg of protein. Moreover while the  $B_{\text{max}}$  values for <sup>125</sup>I-OS<sub>2</sub> and <sup>125</sup>I-OS<sub>1</sub> binding are nearly identical in cultured cells, they are in an ~6:1 ratio in the three other muscle membrane preparations. The easiest interpretation of these results is that rabbit muscle in vivo expresses 2 types (at least) of PLA<sub>2</sub> binding sites, one of which binds both  $OS_2$  and  $OS_1$  and will be referred to as the ' $OS_2/OS_1$ ' binding site. It is the main type of site in skeletal myotubes in culture and is then very highly expressed. The other type of site is much more selective for OS, and it will be referred to as the 'OS2' binding site. This site has apparently the same properties as the neuronal OS2 binding site but are not expressed in skeletal muscle myotube in culture [8]. Such an interpretation is strongly supported by the data in Fig. 3 showing that only about 20% of the total 125 I-OS2 binding is displaceable by OS<sub>1</sub> in skeletal muscle membranes from 18-day-old embryos, whereas 100% of this binding is inhibited by OS, in membranes from myotubes in culture [9] with similar  $K_{0.5}$  values (48 pM v. 34 pM).

The OS<sub>2</sub>/OS<sub>1</sub> receptor found in membranes of cultured skeletal muscle cells is completely insensitive to the bee venom PLA<sub>2</sub> while the brain OS<sub>2</sub> receptor has




Fig. 2. Competition experiments between <sup>125</sup>I-OS<sub>1</sub> and different unlabeled PLA<sub>2</sub>s for the binding to skeletal muscle membranes of 18-day-old rabbit embryos. Membranes (200 µg of protein/ml) were incubated in 0.5 ml with 30 pM <sup>125</sup>I-OS<sub>1</sub> and increasing concentrations of unlabeled OS<sub>1</sub> (~), OS<sub>2</sub> (•) or bee venom PLA<sub>2</sub> (•). Results are expressed as percentage of the maximal specific binding measured in the absence of competitor. 100% corresponds to 3 pM of <sup>125</sup>I-OS<sub>1</sub> specifically bound. Non-specific binding was measured in the presence of 30 nM OS<sub>1</sub> and accounted for 10% of the total binding.




Fig. 3. Competition experiments between <sup>125</sup>I-OS₂ and different unlabeled PLA₂s for the binding to skeletal muscle membranes of 18-day-old rabbit embryos. (A) Membranes (10 µg of protein/ml) were incubated in 1 ml with 22 pM <sup>125</sup>I-OS₂ and increasing concentrations of unlabeled OS₁ (○), OS₂ (●) or bee venom PLA₂ (■). (B) As in (A), except that competition experiments were done in 2 ml with <sup>125</sup>I-OS₂ and unlabeled OS₁ (○) in the presence of 300 nM bee venom PLA₂ or with <sup>125</sup>I-OS₂ and unlabeled bee venom PLA₂ (■) in the presence of m M OS₁. Results are expressed in pM of <sup>125</sup>I-OS₂ specifically bound. Non-specific binding was measured in the presence of 2 nM unlabeled OS₂ and accounted for less than 30% of the total binding. The inset in panel B indicates the maximal inhibition observed with the different unlabeled toxins.

a high affinity for this neurotoxin [8,9]. This suggests that of the two classes of binding sites for  $OS_2$ , the  $OS_2/OS_2$  binding site and the  $OS_2$  binding site, only the  $OS_2$  binding site is recognized by the bee venom  $PLA_2$ . If such an hypothesis is correct, then one would expect that when  $OS_1$  provides a ~20% inhibition of <sup>125</sup>I- $OS_2$  binding (Fig. 3), the bee venom  $PLA_2$  would provide an 80% inhibition. The bee venom  $PLA_2$  indeed inhibits <sup>125</sup>I- $OS_2$  binding by ~80% with a  $K_{0.5}$  value of 120 pM (Fig. 3A). Moreover, as expected, a mixture of  $OS_1$  and bee venom  $PLA_2$  completely inhibits <sup>125</sup>I- $OS_2$  binding (Fig. 3B) with  $K_{0.5}$  values of 58 pM and 36 pM, respectively. Competition experiments with unlabeled  $OS_2$  resulted in a 100% inhibition with a  $K_{0.5}$  value of 12 pM (Fig. 3).

The protein compositions of the neuronal (OS<sub>2</sub> type) and myotube (OS<sub>2</sub>/OS<sub>1</sub> type) PLA<sub>2</sub> receptors are very different. The OS<sub>2</sub> type of receptor is made of major components of mol. wt. 82, 48 and 34 kDa [8,9]. The OS<sub>1</sub>/OS<sub>2</sub> type is made up of only component of 180 kDa




Fig. 4. Cross-linking experiments of <sup>125</sup>I-OS<sub>2</sub> and <sup>125</sup>I-OS<sub>3</sub> to skeletal muscle membranes of 18-day-old rabbit embryos. (A and B) Membranes (300 μg of protein/ml) were incubated with 300 pM <sup>125</sup>I-OS<sub>2</sub> in the absence (lanes 2.18) or the presence of increasing concentrations of OS<sub>2</sub> (lanes 3–6). OS<sub>1</sub> (lanes 8–11) or bee venom PLA<sub>2</sub> (lanes 13–16), cross-linked with 50 μM DSS and loaded onto a 4–14% SDS-polyacrylamide gel under reducing conditions. Coomassie blue staining (A) and autoradiogram patterns (B) of the gel are shown. (C) Membranes (300 μg of protein/ml) were incubated with 250 pM <sup>125</sup>I-OS<sub>1</sub> in the absence (lane 1) or the presence (lane 2) of 30 nM OS<sub>1</sub>, cross-linked with 50 μM DSS and loaded onto a 4–14% SDS-polyacrylamide gel under reducing conditions. Only the autoradiogram patterns are represented. In all panels, 100 μg of proteins were loaded in each track. The position of the M<sub>τ</sub> markers (lanes 1, 7, 12 and 17) are indicated (myosin, 200 000; β-galactosidase, 116 200; phosphorylase B, 97 400; bovine serum albumin, 66 200; ovalbumin, 42 700; carbonic anhydrase, 31 000; soybean trypsin inhibitor, 21 500; cytochrome c, 14 400; from Bio-Rad). Gels were exposed on Kodak X Omat AR film for 4 days (panels A and B) or 7 days (C).

[9]. Cross-linking experiments have been performed on membranes of embryonic muscle using both <sup>125</sup>I-OS<sub>1</sub> and <sup>125</sup>I-OS<sub>2</sub> as markers. All the experiments were car-

ried out with DSS at a concentration of 50  $\mu$ M which does not produce detectable changes in the electrophoretic pattern of membrane proteins (Fig. 4A). The label-

Table I

Binding properties of <sup>125</sup>I-OS<sub>2</sub> and <sup>125</sup>I-OS<sub>1</sub> on different skeletal muscle membrane preparations

Development stage	Direct binding experiments							Competition experiments			
	<sup>125</sup> I-CS <sub>2</sub>					125 I-OS <sub>1</sub>		<sup>125</sup> I-OS <sub>2</sub> /OS <sub>1</sub>		<sup>125</sup> I-OS <sub>1</sub> /OS <sub>2</sub>	
	<i>K</i> <sub>d</sub> <sup>a</sup> (pM)	K <sub>d</sub> <sup>a</sup> (pM)	B <sub>max</sub> <sup>a</sup> fmol/ mg protein)	B <sub>max</sub> <sup>b</sup> (fmol/mg protein)	B <sub>max</sub> "+B <sub>max</sub> " fmol/ mg protein)	K <sub>d</sub> (pM)	B <sub>max</sub> (fmol/mg protein)	<i>K</i> <sub>0.5</sub> (pM)	Inhibition (%)	K <sub>0.5</sub> (p <b>M</b> )	Inhibition (%)
Primary cultured cells Embryos, 18-day-old Neonates, 4-day-old Adult	7.4±0.9 2±1.5 4±2.3 17±5	33±9 46±12	1900±200 67±15 29±8.5 8±3	203±35 86±13	1900±200 271±50 115±21.5 8±3	34±8 48±10 44±9 30±12	1820±150 40±12 18±7 2±1.4	34±6 41±5 39±7 63±10	100 20 23 25	10±4 18±5 20±4 15±3	100 100 100 100

A membrane preparation of differentiated myotubes or crude microsomal fractions of rabbit skeletal muscle removed at several stages of development were incubated with increasing <sup>125</sup>I-toxin concentrations for direct binding experiments, or a fixed <sup>125</sup>I-toxin concentration and various concentrations of unlabeled toxin, for competition experiments as defined in Figs. 1 or 2 and 3, respectively. The protein concentrations used in primary cultured cells and 4-day-old neonates binding experiments were 2 and 20 µg of protein/ml for <sup>125</sup>I-OS<sub>1</sub>, respectively. Each value is the mean ± SE of at least two independent experiments performed in duplicate.

<sup>\*</sup> High affinity component binding site

b Low affinity component binding site

ing pattern obtained with  $^{125}I\text{-OS}_2$  as ligand was complex (Fig. 4B). The major labeled polypeptide components had mol. wts. of 180, 82, 48 and 34 kDa (after subtraction for toxin contribution assuming a 1:1 stoichiometry and a toxin molecular mass of 14 kDa). The specificity of this labeling pattern was demonstrated by the concentration-dependent protection observed with OS<sub>2</sub> (Fig. 4B, lanes 3–6) consistent with its  $K_{0.5}$  value (370 pM) found under the same experimental conditions (not shown). Components of mol.wt. of 82, 48 and 34 kDa were of the same size as those previously identified in rabbit brain membranes [9]. The component of mol.wt. 180 kDa is present in very low amounts in brain membranes but is the only one labeled in cultured muscle cells [9].

When covalent labeling with <sup>125</sup>I-OS<sub>2</sub> was protected by unlabeled OS<sub>1</sub> instead of OS<sub>2</sub>, only the component of 180 kDa disappeared (Fig. 4B, lanes 8–11). Conversely, protection by the bee venom PLA<sub>2</sub> only protected the other bands, leaving unchanged the labeling of the 180 kDa polypeptide (Fig. 4B, lanes 13–16). Finally, in affinity labeling experiments performed with <sup>125</sup>I-OS<sub>1</sub> as marker, only the 180 kDa band was detected (Fig. 4C). Taken all together, these cross-linking experiments clearly indicate again that both types of PLA<sub>2</sub> receptors, the myotube type OS<sub>2</sub>/OS<sub>1</sub> binding sites (180 kDa) and the neuronal-like type OS<sub>2</sub> binding sites, co-exist in rabbit skeletal muscle and that they can be discriminated by OS<sub>1</sub> and by the bee venom PLA<sub>2</sub>.

The relative densities of the different types of PLA<sub>2</sub> receptors vary during rabbit skeletal muscle development. The amount of the OS<sub>2</sub>/OS<sub>1</sub> receptor (180 kDa) is extremely high in aneurally cultured rabbit skeletal muscle cells and decreases throughout the in vivo development (Table I). The neuronal OS<sub>2</sub> type of PLA<sub>2</sub> receptors is not expressed in culture but is highly ex-

pressed in vivo at the embryonic stage. The expression of these PLA<sub>2</sub> receptors is then developmentally regulated and probably greatly influenced by factors such as innervation, growth factors, hormones and/or muscle contractile activity.

The exact physiological function of the different types of PLA, binding sites remains to be elucidated.

Acknowledgements: We thank M.-M. Larroque, C. Roulinat and F. Aguila for expert technical assistance. This work was supported by the Centre National de la Recherche Scientifique, the Association des Myopathes de France, and Ministère de la Défense Nationale (Grant DRET 90/192).

#### REFERENCES

- Broad, A.J., Sutherland, S.K. and Coulter, A.R. (1979) Toxicon 17, 661-664.
- [2] Howard, B.D. and Gundersen, C.B. (1980) Annu. Rec. Pharmacol. Toxicol. 20, 307-336.
- [3] Lee, C.Y., Ho, C.L. and Eaker, D. (1977) Toxicon 18, 443-454.
- [4] Gopalakrishnakone, P., Dempster, D.W., Howgood, B.J. and Elder, H.Y. (1984) Toxicon 22, 85-98.
- [5] Verheij, H.M., Boffa, M.C., Rothen, C., Bryckaert, M.C., Verger, R. and De Hass, G.H. (1980) Eur. J. Biochem. 112, 25-32.
- [6] Condrea, E., Fletcher, J.E., Rapuano, B.E., Yang, C.C. and Rosenberg, P. (1981) Toxicon 19, 705-720.
- [7] Strong, P.N. (1987) in: Cellular and Mulecular Basis of Choliner-gic Function (Dowdall M.J. and Howthorne J.N. eds.) pp. 534-549, Elles Horwoods, Chichester, U.K.
- [8] Lambeau, G., Barhanin, J., Schweitz, H., Qar, J. and Lazdunski, M. (1989) J. Biol. Chem. 264, 11503-11510.
- [9] Lambeau, G., Schmid-Alliana, A., Lazdunski, M. and Barhanin, J. (1990) J. Biol. Chem. 265, 9526-9532.
- [10] Shipolini, R.A., Callewaert, G.L., Cottrell, R.C., Doonan, S., Vernon, C.A. and Banks, B.E.C. (1971) Eur. J. Biochem. 20, 459-468.
- [11] Lambeau, G., Lazdunski, M. and Barhanin, J. (1991) Neurochem. Res. 16, 651-658.
- [12] Bradford, M.M. (1976) Anal. Biochem. 72, 248-254.
- [13] Laemmli. U.K. (1970) Nature 227, 680-685.